Kasper S, el Giamal N, Hilger E
Department of General Psychiatry, University of Vienna, Austria.
Expert Opin Pharmacother. 2000 May;1(4):771-82. doi: 10.1517/14656566.1.4.771.
Several treatment approaches are available for treatment of depression. However, reboxetine is the first selective noradrenaline re-uptake inhibitor. Whereas formerly only noradrenaline re-uptake inhibitors with a mixed mechanism of action were available. These included action not only at noradrenergic, but also at serotonergic and other neurotransmitter-sites. Thus, reboxetine represents the first of a new class of antidepressant agents with specificity for the noradrenergic system. Reboxetine has been shown to be an effective first-line treatment for patients with all grades of depression, to be effective in the prevention of relapse and recurrence and to offer significant benefits in terms of relieving the impaired social functioning associated with depressive disorders. Reboxetine was significantly superior to the serotonergic compound fluoxetine in improvement of social functioning in both the general depressed population and in those patients who achieved symptomatic remission, indicating a superior quality of remission. Altogether reboxetine was well tolerated during the acute and long-term treatment phase; side-effects such as increased sweating, constipation and dry mouth were the most prominent to be reported. The availability of reboxetine represents a significant addition to the currently available pharmacologic armamentarium for the treatment of depression.
有几种治疗方法可用于治疗抑郁症。然而，瑞波西汀是第一种选择性去甲肾上腺素再摄取抑制剂。而以前只有作用机制混合的去甲肾上腺素再摄取抑制剂。这些抑制剂不仅作用于去甲肾上腺素能位点，还作用于血清素能和其他神经递质位点。因此，瑞波西汀代表了一类对去甲肾上腺素能系统具有特异性的新型抗抑郁药中的第一种。瑞波西汀已被证明是治疗各级抑郁症患者的有效一线治疗药物，对预防复发和再发有效，并在缓解与抑郁症相关的社会功能受损方面具有显著益处。在改善一般抑郁症患者和症状缓解患者的社会功能方面，瑞波西汀显著优于血清素能化合物氟西汀，表明缓解质量更高。总体而言，瑞波西汀在急性和长期治疗阶段耐受性良好；报告最多的副作用是出汗增加、便秘和口干。瑞波西汀的出现是目前可用于治疗抑郁症的药物库的一个重要补充。
